[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.163.147.69. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Article
July 1977

Bullous PemphigoidClinical and Serologic Evaluation for Associated Malignant Neoplasms

Author Affiliations

From the Departments of Dermatology, State University of New York at Buffalo School of Medicine (Drs Ahmed and Provost), and Diagnostic Immunology, Roswell Park Memorial Institute (Dr Chu), Buffalo. Dr Ahmed is now with the University of California at Los Angeles School of Medicine.

Arch Dermatol. 1977;113(7):969. doi:10.1001/archderm.1977.01640070103017
Abstract

Bullous pemphigoid (BP) has been reported in association with malignant neoplasms of the urinary tract, lung, genitalia, breast, pancreas, gastrointestinal (GI) tract, skin, and lymphoreticular system.1 The course of BP usually does not parallel the course of the malignant neoplasm. The malignant neoplasm may be evident at the onset of BP or present as an incidental finding at postmortem examination.2

Carcinoembryonic antigen (CEA) levels greater than 2.5 ng/ml have been reported in serum samples from patients with pancreatic, colonic, rectal, gastric, mammary, and cervical malignant neoplasms, and in some leukemias.3 The presence of CEA correlates with a high incidence of proved malignant neoplasms and is an early indicator of clinically unrecognized recurrence.4

The purpose of this study was to determine the incidence of a malignant neoplasm in a large number of patients with BP using clinical as well as serologic evaluation.

Subjects and Methods  Thirty-three patients

First Page Preview View Large
First page PDF preview
First page PDF preview
×